The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups
June 27, 2017
-
BUSINESS Sumitomo Dainippon’s Napabucasin Stumbles on PIII Gastric Cancer Study
June 27, 2017
-
BUSINESS Daiichi Sankyo Confident of Achieving US$1 Billion Sales for Edoxaban
June 26, 2017
-
REGULATORY Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
-
BUSINESS Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
-
BUSINESS Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
-
ORGANIZATION FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
-
BUSINESS Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
-
TRENDS Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
REGULATORY 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
-
REGULATORY (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
-
REGULATORY Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
-
ACADEMIA Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
-
ORGANIZATION JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
-
REGULATORY Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
-
REGULATORY Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
-
ORGANIZATION JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
-
BUSINESS FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
-
BUSINESS Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
-
BUSINESS Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…